Abstract
The role of polysaccharides in the pathogenesis of Alzheimer disease (AD) is unclear. However, in light of studies indicating impaired glucose utilization in AD and increased activation of the hexosamine pathway that is seen with hyperglycemia, in the brains of patients with AD, aberrantly high levels of glucosamine may result in synthesis of glucosamine polymers such as chitin, a highly insoluble polymer of N-acetyl glucosamine, linearized by b1-4 linkages. To examine this further, we studied brain tissue at autopsy from subjects with sporadic and familial AD using calcofluor histochemistry. Calcofluor excites on exposure to ultraviolet light and exhibits a high affinity for chitin in vivo by interacting with b1-4 linkages. Amyloid plaques and blood vessels affected by amyloid angiopathy showed bright fluorescence. Moreover, treatment with chitinase, followed by b-N-acetyl glucosaminidase showed a decrease in calcofluor fluorescence. Since chitin is a highly insoluble molecule and a substrate for glycan-protein interactions, chitin-like polysaccharides within the brain could facilitate nucleation of amyloid proteins in various amyloidoses including AD.
Keywords: alzheimer disease, amyloid, chitin, n-acetyl glucosamine
Current Alzheimer Research
Title: Chitin-like Polysaccharides in Alzheimers Disease Brains
Volume: 2 Issue: 4
Author(s): Rudy J. Castellani, Sandra L. Siedlak, Anne E. Fortino, George Perry, Bernardino Ghetti and Mark A. Smith
Affiliation:
Keywords: alzheimer disease, amyloid, chitin, n-acetyl glucosamine
Abstract: The role of polysaccharides in the pathogenesis of Alzheimer disease (AD) is unclear. However, in light of studies indicating impaired glucose utilization in AD and increased activation of the hexosamine pathway that is seen with hyperglycemia, in the brains of patients with AD, aberrantly high levels of glucosamine may result in synthesis of glucosamine polymers such as chitin, a highly insoluble polymer of N-acetyl glucosamine, linearized by b1-4 linkages. To examine this further, we studied brain tissue at autopsy from subjects with sporadic and familial AD using calcofluor histochemistry. Calcofluor excites on exposure to ultraviolet light and exhibits a high affinity for chitin in vivo by interacting with b1-4 linkages. Amyloid plaques and blood vessels affected by amyloid angiopathy showed bright fluorescence. Moreover, treatment with chitinase, followed by b-N-acetyl glucosaminidase showed a decrease in calcofluor fluorescence. Since chitin is a highly insoluble molecule and a substrate for glycan-protein interactions, chitin-like polysaccharides within the brain could facilitate nucleation of amyloid proteins in various amyloidoses including AD.
Export Options
About this article
Cite this article as:
Castellani J. Rudy, Siedlak L. Sandra, Fortino E. Anne, Perry George, Ghetti Bernardino and Smith A. Mark, Chitin-like Polysaccharides in Alzheimers Disease Brains, Current Alzheimer Research 2005; 2 (4) . https://dx.doi.org/10.2174/156720505774330555
DOI https://dx.doi.org/10.2174/156720505774330555 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Thrombosis in Paroxysmal Nocturnal Hemoglobinuria at a Glance: A Clinical Review
Current Vascular Pharmacology Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update
Mini-Reviews in Medicinal Chemistry Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice
Current Vascular Pharmacology Decreased Expression of Sox-1 in Cerebellum of Rat with Generalized Seizures Induced by Kindling Model
CNS & Neurological Disorders - Drug Targets Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link?
Current Neuropharmacology Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Retromer's Role in Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases
Current Protein & Peptide Science Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias
CNS & Neurological Disorders - Drug Targets Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Role of the Transglutaminase Enzymes in the Nervous System and their Possible Involvement in Neurodegenerative Diseases
Current Medicinal Chemistry Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Therapeutic Potential of Neuregulin in Cardiovascular System: Can we Ignore the Effects of Neuregulin on Electrophysiology?
Mini-Reviews in Medicinal Chemistry Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design